BioMAdvanced Diagnostics

This new accolade joins our previous recognitions: - 🏆 2021: Prix de la Région Pays de la Loire at Start West. - 🏆 2022: Award for job creation at Startups & Innovation Day Each award reminds us of all the progress we've made since our launch in 2021.

Last week, our CEO Frédéric Pette proudly received a trophy from @bpifrance, marking BioMAdvanced Diagnostics' selection to join the prestigious Club Excellence. #Atlanpole #AtlanpoleBiotherapies #LaFrenchCare #medtech

🚀 [Q1 2024 – recap] Our first 3 months of 2024 have already been marked by several key milestones, enabling us to stay confident about our current scheduled roadmap and to prepare for a global launch. Details : biomadvanced-diagnostics.com/newsevents-2/q… #MedTech #LaFrenchCare

Why can we reach the market faster than most biotech companies and other medtech ? 1️⃣ THE ABILITY TO ADOPT AN AGILE DEVELOPMENT PROCESS 2️⃣ A MORE STREAMLINED REGULATORY APPROVAL PROCESS 3️⃣ THE USE OF BIO-COLLECTIONS biomadvanced-diagnostics.com/newsevents-2/w… #nantes #medtech

Wondering how we're able to process our clinical trials at such a rapid pace? The secret lies in Bio-collections (or Biobanks). These collections of samples (blood, biopsies, etc.) and clinical data, gathered from patients recruited without bias. #MedTech

“BioMAdvanced Diagnostics” and its logo have been successfully registered as Trademarks in the United States of America. Another step in our journey towards delivering great diagnostics solutions to transplanted patients and their clinicians around the world! #medtech #nantes

Why does this matter ? Companies involved in the development and manufacturing of Medical Devices are REQUIRED to have a Certified Quality System in accordance with the ISO 13485 standard.

[Milestone] BiomAdvanced Diagnostics is ISO 13485 certified by BSI under certificate number MD 775018. #ISO13485 #RegulatoryAffairs #MedTech

These tests were conducted independently on two separate days under the supervision of our team. ▶▶▶We are pleased to announce that the product has met all of our expectations. (5/5)

📌In pursuit of this objective, two Medical Biology Engineers from a leading French University Hospital biology lab visited our own molecular biology lab. Without prior knowledge of the product, they conducted tests solely relying on the provided instructions for use. (4/5)

Crucial to our product : its ease of use and its safety. How do we ensure it ? By conducting specific usability testing (1/5)

We have now converted the option into a tangible reality by signing the definitive license agreement. This move opens a vast market encompassing 25 million patients globally, grappling with cancer or kidney failure and facing the looming threat of irreversible muscular atrophy.

This agreement was an option - 3 additional steps were needed from Clermont Auvergne Innovation for us to confidently move forward. 👏It only took the Clermont teams 6 months to accomplish those 3 steps. This rapid execution and its quality show the teams' remarkable efficiency.

We signed a new licence agreement opening a market of 25 million patients worldwide suffering from cancer or kidney failure and at risk for an irreversible muscular atrophy.

BioMAdvanced Diagnostics has been selected to join the very selective @Bpifrance CLUB EXCELLENCE. 🚀 Among the 200 K companies supported by Bpifrance, only 2,000 companies, including startups, small and med-size companies, and intermediary size companies (ETI), have been chosen

Last week [Atlanpole Forum] It has become an annual tradition for our CEO, Frederic Pette : attending the @atlanpole Forum. Always invigorating to participate in this event, connect with fellow entrepreneurs, and engage with the entire ecosystem. #Paysdelaloire #frenchtech

Fundraising, product development key milestones, a licence agreement strengthening our IP, big headways on the regulatory front…A new year always gives the opportunity to reflect on the previous year. Here is a full recap of key milestones & achievements biomadvanced-diagnostics.com/newsevents-2/2…